{{Rsnum
|rsid=1058930
|Gene=CYP2C8
|Chromosome=10
|position=96818119
|Orientation=minus
|GMAF=0.02571
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 86.7 | 13.3 | 0.0
| HCB | 99.3 | 0.7 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 99.3 | 0.7 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 99.3 | 0.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 98.0 | 2.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 94.8 | 5.2 | 0.0
| MKK | 96.8 | 3.2 | 0.0
| TSI | 90.2 | 9.8 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1058930
|Name_s=CYP2C8: I264M; C792G
|Gene_s=CYP2C8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12429347
|Annotation=Alleles positive for this variant are designated CYP2C8*4. In in vitro experiments, the paclitaxel 6 alpha-hydroxylase acivity associated with CYP2C8*4 appeared lower than the wildtpe but the difference was not significant.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161660846
}}

{{PMID Auto
|PMID=17048007
|Title=Association of warfarin dose with genes involved in its action and metabolism.
|OA=1
}}

{{PMID Auto
|PMID=18769365
|Title=Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.
|OA=1
}}

{{PMID Auto
|PMID=19761371
|Title=Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
|OA=1
}}

{{PMID Auto
|PMID=20389299
|Title=Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
|OA=1
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}